Advertisement

Apoptosis

, Volume 7, Issue 6, pp 537–548 | Cite as

Comparison of anthracycline-induced death of human leukemia cells: Programmed cell death versus necrosis

  • D. C. Dartsch
  • A. Schaefer
  • S. Boldt
  • W. Kolch
  • H. Marquardt
Article

Abstract

We investigated the mode of cell death induced by the anthracyclines, aclarubicin, doxorubicin and daunorubicin in the human leukemia cell lines, HL60 and Jurkat. The cells were incubated with drug concentrations up to 500 nM for periods between 3 and 24 hours, followed by morphological and biochemical analyses. All three substances induced DNA fragmentation, evident as DNA laddering and appearance of cells with hypodiploid DNA content, externalisation of phosphatidyl serine, activation of caspases and degradation of the apoptosis-specific endonuclease inhibitor DFF45. However, concentrations and times necessary for these effects to occur were different, aclarubicin being the quickest acting drug with a lag phase of 3 h, followed by daunorubicin with 6 h and doxorubicin with 24 h. More importantly, aclarubicin induced these effects while the cell membrane was intact, whereas doxorubicin and daunorubicin led to immediate loss of membrane integrity. Programmed cell death is characterised by preservation of membrane integrity in order to allow removal of apoptotic bodies, whereas cell rupture is an early event in necrosis. We therefore suggest that, in our experimental settings, doxorubicin- and daunorubicin-induced cell death occurs by necrosis, while aclarubicin induces programmed cell death.

anthracyclines apoptosis caspases DFF45 membrane integrity necrosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Desoize B, Sen S L'apoptose ou mort cellulaire programmée: Concepts, méchanismes et apports en cancérologie. Bull Cancer 1992; 79: 413–425.PubMedGoogle Scholar
  2. 2.
    Cohen JJ Apoptosis. Immunol Today 1993; 14: 126–130.PubMedGoogle Scholar
  3. 3.
    Hannun YA Apoptosis and the dilemma of cancer chemotherapy. Blood 1997; 89: 1845–1853.PubMedGoogle Scholar
  4. 4.
    Kerr JFR, Wyllie AH, Currie AR Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239–257.PubMedGoogle Scholar
  5. 5.
    Wyllie AH Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284: 555–556.PubMedGoogle Scholar
  6. 6.
    Umansky SR Apoptosis: Molecular and cellular mechanisms (A review). Mol Biol 1996; 30: 285–295.Google Scholar
  7. 7.
    Wyllie A Apoptosis. An endonuclease at last. Nature 1998; 391: 20–21.PubMedGoogle Scholar
  8. 8.
    Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1b-converting enzyme. Cell 1993; 75: 641–652.CrossRefPubMedGoogle Scholar
  9. 9.
    Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148: 2207–2216.PubMedGoogle Scholar
  10. 10.
    Mayer P, Carpentier Y, Gorisse MC, Desoize B Culture conditions modulate the effects of Aclacinomycin A on growth, differentiation and apoptosis of HL-60 cells. Anticancer Res 1994; 14: 2331–2338.PubMedGoogle Scholar
  11. 11.
    Côme MG, Skladanowski A, Larsen AK, Laurent G Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells. Br J Cancer 1999; 79: 1090–1097.PubMedGoogle Scholar
  12. 12.
    Efferth T, Fabry U, Osieka R Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 1997; 11: 1180–1186.PubMedGoogle Scholar
  13. 13.
    Labroille G, Dumain P, Lacombe F, Belloc F Flow cytometric evaluation of Fas expression in relation to response and resistance to anthracyclines in leukemic cells. Cytometry 2000; 39: 195–202.PubMedGoogle Scholar
  14. 14.
    Quillet-Mary A, Mansat V, Duchayne E, et al Daunorubicininduced internucleosomal DNA fragmentation in acute myeloid cell lines. Leukemia 1996; 10: 417–425.PubMedGoogle Scholar
  15. 15.
    Turnbull KJ, Brown BL, Dobson PR Caspase-3-like activity is necessary but not sufficient for daunorubicin-induced apoptosis in Jurkat human lymphoblastic leukemia cells. Leukemia 1999; 13: 1056–1061.PubMedGoogle Scholar
  16. 16.
    Ferraro C, Quemeneur L, Prigent AF, Taverne C, Revillard JP, BonnefoyBerard N Anthracyclines trigger apoptosis of both G(0)-G(1) and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells. Cancer Res 2000; 60: 1901–1907.PubMedGoogle Scholar
  17. 17.
    Belaud-Rotureau MA, Durrieu F, Labroille G, et al Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment. Leukemia 2000; 14: 1266–1275.PubMedGoogle Scholar
  18. 18.
    Durrieu F, Belloc F, Lacoste L, et al Caspase activation is an early event in anthracycline-induced apoptosis and allows detection of apoptotic cells before they are ingested by phagocytes. Exp Cell Res 1998; 240: 165–175.PubMedGoogle Scholar
  19. 19.
    Jaffrézou JP, Levade T, Bettaieb A, et al Daunorubicin-induced apoptosis: Triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J 1996; 15: 2417–2424.PubMedGoogle Scholar
  20. 20.
    Vial JP, Belloc F, Dumain P, et al Study of the apoptosis induced in vitro by antitumoral drugs on leukaemic cells. Leukemia Res 1997; 21: 163–172.Google Scholar
  21. 21.
    Maestre N, Tritton TR, Laurent G, Jaffrezou JP Cell surfacedirected interaction of anthracyclines leads to cytotoxicity and nuclear factor kappa B activation but not apoptosis signaling. Cancer Res 2001; 61: 2558–2561.PubMedGoogle Scholar
  22. 22.
    McGahon AJ, Costa Pereira AP, Daly L, Cotter TG Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br J Haematol 1998; 101: 539–547.PubMedGoogle Scholar
  23. 23.
    Gamen S, Anel A, Lasierra P, et al Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett 1997; 417: 360–364.PubMedGoogle Scholar
  24. 24.
    Gamen S, Anel A, Perez-Galan P, et al Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsi m loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res 2000; 258: 223–235.PubMedGoogle Scholar
  25. 25.
    Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, Debatin KM Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 2001; 20: 1063–1075.PubMedGoogle Scholar
  26. 26.
    Müller I, Jenner A, Bruchelt G, Niethammer D, Halliwell B Effect of concentration on the cytotoxic mechanism of doxorubicin-apoptosis and oxidative DNA damage. Biochem Biophys Res Comm 1997; 230: 254–257.PubMedGoogle Scholar
  27. 27.
    Bakker M, van der Graaf WTA, Groen HJM, Smit EF, De Vries EGE Anthracyclines-Pharmacology and resistance, a review. Curr Pharmaceut Design 1995; 1: 133–144.Google Scholar
  28. 28.
    Mazué G, Williams GM, Iatropoulos MJ, et al Anthracyclines: Review of genotoxicity and carcinogenicity studies. Int J Oncol 1996; 8: 525–536.Google Scholar
  29. 29.
    Sartorelli AC The 1985 alter Hubert lecture. Malignant cell differentiation as a potential therapeutic approach. Br J Cancer 1985; 52: 293–302.PubMedGoogle Scholar
  30. 30.
    Schaefer A, Steinheider G, Stöcker U, Marquardt H Effects of anthracyclines on cellular differentiation and oncogene expression: Implications for carcinogenesis and cancer chemotherapy. Curr Pharmaceut Design 1995; 1: 15–22.Google Scholar
  31. 31.
    Schaefer A, Dahle M, Radenz G, Steinheider G, Marquardt H Structure-activity relationship between anthracycline-induced differentiation and inhibition of glycoprotein synthesis in friend erythroleukemia cells. Leukemia 1991; 5: 95–100.Google Scholar
  32. 32.
    Schwartz EL, Sartorelli AC Structure-activity relationships for the induction of differentiation of HL-60 human acute promyelocytic leukemia cells by anthracyclines. Cancer Res 1982; 42: 2651–2655.PubMedGoogle Scholar
  33. 33.
    Schaefer A, Dressel A, Lingelbach K, Schmidt CA, Steinheider G, Marquardt H Induction of differentiation in Friend-erythroleukemia cells by Aclacinomycin A: Early transient decrease in c-myc and c-myb mRNA levels. Leukemia 1992; 6: 828–833.PubMedGoogle Scholar
  34. 34.
    Stöcker U, Schaefer A, Marquardt H DMSO-like rapid decrease in c-myc and c-myb mRNA levels and induction of differentiation in HL-60 cells by the anthracycline antitumor antibiotic aclarubicin. Leukemia 1995; 9: 146–154.PubMedGoogle Scholar
  35. 35.
    Lown JW Anthracycline and anthraquinone anticancer agents: Current status and recent developments. Pharmacol Ther 1993; 60: 185–214.PubMedGoogle Scholar
  36. 36.
    Zunino F, Capranico G DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Design 1990; 5: 307–317.Google Scholar
  37. 37.
    Malisza KL, Mcintosh AR, Sveinson SE, Hasinoff BB Semiquinone free radical formation by daunorubicin aglycone incorporated into the cellular membranes of intact Chinese hamster ovary cells. Free Radical Research 1996; 24: 9–18.PubMedGoogle Scholar
  38. 38.
    Collins SJ The HL-60 promyelocytic leukemia cell line: Proliferation, differentiation and cellular oncogene expression. Blood 1987; 70: 1233–1244.PubMedGoogle Scholar
  39. 39.
    Schneider U, Schwenk HU, Bornkamm G Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 1977; 19: 621–626.PubMedGoogle Scholar
  40. 40.
    Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C A novel assay for apoptosis-Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunological Methods 1995; 184: 39–51.Google Scholar
  41. 41.
    Thiagarajan P, Tait JF Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 1990; 265: 17420–17423.PubMedGoogle Scholar
  42. 42.
    Sabol SL, Li R, Lee TY, Abdul-Khalek R Inhibition of apoptosis-associated DNA fragmentation activity in nonapoptotic cells: The role of DNA fragmentation factor-45 (DFF45/ICAD). Biochem Biophys Res Commun 1998; 253: 151–158.PubMedGoogle Scholar
  43. 43.
    Blagosklonny MV Cell death beyond apoptosis. Leukemia 2000; 14: 1502–1508.PubMedGoogle Scholar
  44. 44.
    Gonzalez VM, Fuertes MA, Alonso C, Perez JM Is cisplatininduced cell death always produced by apoptosis? Mol Pharmacol 2001; 59: 657–663.PubMedGoogle Scholar
  45. 45.
    Kiaris H, Schally AV Apoptosis versus necrosis: Which should be the aim of cancer therapy? Proc Soc Exp Biol Med 1999; 221: 87–88.PubMedGoogle Scholar
  46. 46.
    Zörnig M, Hueber A, Baum W, Evan G Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 2001; 1551: F1–37.Google Scholar
  47. 47.
    Schulze-Osthoff K, Walczak H, Droge W, Krammer PH Cell nucleus andDNAfragmentation are not required for apoptosis. J Cell Biol 1994; 127: 15–20.PubMedGoogle Scholar
  48. 48.
    Johnson DE Programmed cell death regulation: Basic mechanisms and therapeutic opportunities. Leukemia 2000; 14: 1340–1344.PubMedGoogle Scholar
  49. 49.
    Ormerod MG The study of apoptotic cells by flow cytometry. Leukemia 1998; 12: 1013–1025.PubMedGoogle Scholar
  50. 50.
    Egorin MJ, Clawson RE, Ross LA, Schlossberger NM, Bachur NR Cellular accumulation and disposition of aclacinomycin A. Cancer Res 1979; 39: 4396–4400.PubMedGoogle Scholar
  51. 51.
    Egorin MJ, Clawson RE, Ross LA, Bachur NR Cellular pharmacology of N,N-dimethyl daunorubicin and N,N-dimethyl adriamycin. Cancer Res 1980; 40: 1928–1933.PubMedGoogle Scholar
  52. 52.
    Schaefer A, Westendorf J, Lingelbach K, et al Decreased resistance to N,N-dimethylated anthracyclines in multidrugresistant Friend erythroleukemia cells. Cancer Chemother Pharmacol 1993; 31: 301–307.PubMedGoogle Scholar
  53. 53.
    Morjani H, Millot JM, Belhoussine R, Sebille S, Manfait M Anthracycline subcellular distribution in human leukemic cells by microspectrofluorometry: Factors contributing to drug-induced cell death and reversal of multidrug resistance Leukemia 1997; 11: 1170–1179.PubMedGoogle Scholar
  54. 54.
    Gieseler F, Nussler V, Brieden T, Kunze J, Valsamas S Intracellular pharmacokinetics of anthracyclines in human leukemia cells: Correlation of DNA-binding with apoptotic cell death. Int J Clin Pharmacol Ther 1998; 36: 25–28.PubMedGoogle Scholar
  55. 55.
    Goldenberg GJ, Wang H, Blair GW Resistance to adriamycin: Relationship of cytotoxicity to drug uptake and DNA singleand double-strand breakage in cloned cell lines of adriamycinsensitive and-resistant P388 leukemia. Cancer Res 1986; 46: 2978–2983.PubMedGoogle Scholar
  56. 56.
    Supino R, Mariani M, Capranico G, Colombo A, Parmiani G Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line. Br J Cancer 1988; 57: 142–146.PubMedGoogle Scholar
  57. 57.
    Tritton TR Cell surface actions of adriamycin. Pharmacol Ther 1991; 49: 293–309.PubMedGoogle Scholar
  58. 58.
    Goormaghtigh E, Pollakis G, Ruysschaert JM Mitochondrial membrane modifications induced by adriamycin-mediated electron transport. Biochem Pharmacol 1983; 32: 889–893.PubMedGoogle Scholar
  59. 59.
    Mimnaugh EG, Kennedy KA, Trush MA, Sinha BK Adriamycin-enhanced membrane lipid peroxidation in isolated rat nuclei. Cancer Res 1985; 45: 3296–3304.PubMedGoogle Scholar
  60. 60.
    Mazué G, Iatropoulos MJ, Imondi AR, et al Anthracyclines: A review of general and special toxicity studies. Int J Oncol 1995; 7: 713–726.Google Scholar
  61. 61.
    Scott CA, Westmacott D, Broadhurst MJ, Thomas GJ, Hall MJ 9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures. Br J Cancer 1986; 53: 595–600.PubMedGoogle Scholar
  62. 62.
    Marquardt H, Phillips FS, Sternberg SS Tumorigenicity in vivo and induction of malignant transformation and mutagenesis in cell cultures by adriamycin and daunomycin. Cancer Res 1976; 36: 2065–2069.PubMedGoogle Scholar
  63. 63.
    Westendorf J, Marquardt H, Ketkar MB, Mohr U, Marquardt H Tumorigenicity in vivo and induction of mutagenesis and DNA repair in vitro by aclacinomycin A and marcellomycin: Structure-activity relationship and predicitve value of short term tests. Cancer Res 1983; 43: 5248–5251.PubMedGoogle Scholar
  64. 64.
    Kern W, Braess J, Grote-Metke A, et al Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: Results of a prospective multicenter phase II trial. German AML Cooperative Group. Leukemia 1998; 12: 1522–1526.PubMedGoogle Scholar
  65. 65.
    Yamada K, Furusawa S, Saito K, et al Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: A pilot study. Leukemia 1995; 9: 10–14.PubMedGoogle Scholar
  66. 66.
    Liwo A, Jeziorek D, Ossowski T, et al Molecular modeling of singlet-oxygen binding to anthraquinones in relation to the peroxidating activity of antitumor anthraquinone drugs. Acta Biochim Pol 1995; 42: 445–456.PubMedGoogle Scholar
  67. 67.
    Singal PK, Iliskovic N, Li T, Kumar D Adriamycin cardiomyopathy: Pathophysiology and prevention. FASEB J 1997; 11: 931–936.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • D. C. Dartsch
    • 1
  • A. Schaefer
    • 1
  • S. Boldt
    • 2
  • W. Kolch
    • 1
  • H. Marquardt
    • 1
  1. 1.Department of ToxicologyHamburg University Medical SchoolHamburgGermany
  2. 2.CRC Beatson Institute for Cancer ResearchGlasgowUK

Personalised recommendations